Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics director Claire Mazumdar received a new stock option grant. The Form 4 reports an award of options covering 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date and expire on June 8, 2036. After this grant, Mazumdar holds stock options for 32,947 underlying shares directly.
Relay Therapeutics director Habib J. Dable received a new stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036. It vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual stockholder meeting. Following this grant, Dable holds options covering 32,947 underlying shares directly.
Relay Therapeutics director Linda A. Hill received a stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted as a compensation award, not an open-market purchase or sale.
The option was granted on June 9, 2026 and vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following that date. The option expires on June 8, 2036 if not exercised.
Relay Therapeutics, Inc. director Alexis Borisy reported receiving a stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036.
According to the filing, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that grant date. This is a compensation-related grant, not an open-market purchase or sale of shares.
Relay Therapeutics director Douglas S. Ingram received a grant of stock options covering 32,947 shares of common stock. The options carry an exercise price of $14.09 per share and were granted as a compensation-related award, not an open-market purchase or sale.
According to the terms, the award vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders following that grant date. After this grant, Ingram holds options for 32,947 underlying shares.
Relay Therapeutics, Inc. director Lonnel Coats received a new stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted on June 9, 2026 as compensation, not an open-market purchase.
The option vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Coats holds stock options for 32,947 underlying shares directly.
Relay Therapeutics director Mark Murcko received a new stock option award. The grant covers 32,947 shares of common stock at an exercise price of $14.09 per share and expires on June 8, 2036.
According to the terms, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Murcko holds options for 32,947 shares directly.
Relay Therapeutics reported results from its 2026 annual stockholder meeting and a key charter change. Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and the company filed a Certificate of Second Amendment in Delaware to implement this change.
Two Class III directors, Douglas S. Ingram and Claire Mazumdar, Ph.D., were elected for terms ending at the 2029 annual meeting. Stockholders also approved, on a non-binding basis, the compensation of named executive officers and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Relay Therapeutics, Inc. entered into an underwriting agreement with Jefferies and TD Securities for an underwritten public offering of 22,916,667 shares of common stock at $12.00 per share. Underwriters received a 30-day option for up to 3,437,500 additional shares, which was exercised in full on May 21, 2026.
The company expects net proceeds of approximately $296.8 million after underwriting discounts and expenses. The offering, made off an effective Form S-3ASR shelf using a May 20, 2026 prospectus supplement, is expected to close on May 22, 2026, subject to customary conditions.
Relay Therapeutics is offering 22,916,667 shares of common stock at $12.00 per share. The prospectus supplement dated May 20, 2026 states estimated net proceeds of approximately $258.0 million (about $296.8 million if the underwriters exercise their 30-day option in full for an additional 3,437,500 shares). The offering assumes 189,209,453 shares outstanding as of March 31, 2026. Net tangible book value per share would be $4.24 after the offering, producing immediate dilution of $7.76 per new share. Proceeds are planned to fund research and clinical development, working capital, capital expenditures and general corporate purposes.